Studies have demonstrated that expression of PD-L1 in tumor cells and tumor-infiltrating immune cells in bladder cancer can select for patients that are more likely to benefit from such treatments [12, 37]. This evidence concerns the gene CD274 and urinary bladder carcinoma.